<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[Biogen Idec Inc. | Company News & Executive Profiles - BIIB | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/biogen+idec+inc..html?i=11]]></link>
	<description><![CDATA[Latest company news & analysis, recent events, stock quotes, earning call transcripts, with profiles and descriptions of top business executives for Biogen Idec Inc.]]></description>
	<s:counts start="0" returned="10" found="546" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Biogen Idec Blinks: Is It Enough for Facet Biotech, or Will the Drama Continue?]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005676/biogen-idec-blinks-is-it-enough-for-facet-biotech-or-will-the-drama-continue/]]></link>
		<description><![CDATA[Biogen Idec BIIB says $17.50 per share is its final offer for Facet Biotech FACT, its partner on multiple sclerosis drug daclizumab. But analysts aren't so sure this biotech soap opera is really nearing its season finale. by Trista Morrison]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Sun, 06 Dec 2009 21:25:05 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biogen+idec+inc..html"><![CDATA[Biogen Idec Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/trista+morrison.html"><![CDATA[Trista Morrison]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BIIB</category>
		<category domain="tickers">BIIB</category>
	</item>
	<item>
		<title><![CDATA[Financing Drug Discovery: Recent Deals]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175397-financing-drug-discovery-recent-deals%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[The Burrill Report submits:  by Marie Daghlian A smattering of deals and financings marked the relatively quiet days before Thanksgiving. San Diego-based biotech Receptos closed a two-tranche $25 million series A financing. The company is focused on identifying and developing best- and first-in-class therapeutic candidates that target a family...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 26 Nov 2009 12:41:16 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/the+burrill+report.html"><![CDATA[The Burrill Report]]></category>
		<category domain="http://resources.bnet.com/topic/biogen+idec+inc..html"><![CDATA[Biogen Idec Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BIIB</category>
		<category domain="tickers">BIIB</category>
	</item>
	<item>
		<title><![CDATA[Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005261/fda-looking-to-regulate-biogens-invisible-salesforce/]]></link>
		<description><![CDATA[On November 2, Biogen Idec updated the prescribing label for its blockbuster multiple sclerosis drug Tysabri natalizumab after consultation with the FDA. Aside from acknowledging that the risk of developing progressive multifocal leukoencephalopathy PML, an often fatal brain infection, increases with longer duration of treatment, no other revisions concerning the...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Thu, 12 Nov 2009 12:19:16 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/risk.html"><![CDATA[Risk]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/social+media.html"><![CDATA[Social Media]]></category>
		<category domain="http://resources.bnet.com/topic/biogen+idec+inc..html"><![CDATA[Biogen Idec Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/strategy.html"><![CDATA[Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/security.html"><![CDATA[Security]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/management.html"><![CDATA[Management]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BIIB</category>
		<category domain="tickers">BIIB</category>
	</item>
	<item>
		<title><![CDATA[More Tysabri Problems; Time for a Biogen-Idec Credibility Check]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005050/moretysabri-problemstime-for-biogen-idec-credibility-check/]]></link>
		<description><![CDATA[Unsubstantiated whisperings about Biogen Idec and its controversial multiple sclerosis drug took an ugly turn to the truth on Thursday  when European regulators disclosed case number 24 of progressive multifocal leukoencephalopathy, a serious brain infection known as PML, in a relapsed MS patient receiving Tysabri natalizumab infusions. With 11...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Fri, 30 Oct 2009 12:59:04 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biogen+idec+inc..html"><![CDATA[Biogen Idec Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/regulations.html"><![CDATA[Regulations]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BIIB</category>
		<category domain="tickers">BIIB</category>
	</item>
	<item>
		<title><![CDATA[EMEA links 24th PML case to Tysabri]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/emea-links-24th-pml-tysabri/18326/]]></link>
		<description><![CDATA[European regulators offer yet another update on Tysabri-linked cases of progressive multifocal leukoencephalopathy: The grand total is now 24, up from 23 last week and just 13 some six weeks ago. Of those 24 patients, four died. The numbers are coming thick and fast now because the European Union is...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Fri, 30 Oct 2009 09:42:07 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/safety.html"><![CDATA[safety]]></category>
		<category domain="http://resources.bnet.com/topic/biogen+idec+inc..html"><![CDATA[Biogen Idec Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BIIB</category>
		<category domain="tickers">BIIB</category>
	</item>
	<item>
		<title><![CDATA[Biogen-Idec's Tysabri Problems May Be Fault of European Doctors]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005010/biogen-idecs-tysabri-problems-may-be-fault-of-european-doctors/]]></link>
		<description><![CDATA[As mentioned in my last BNET Pharma posting, Biogen Idec's key multiple sclerosis drug Tysabri had been linked to 23 worldwide cases of a potentially deadly brain infection called progressive multifocal leukoencephalopathy, or PML -- with most confirmed cases centered in Europe, in particular Germany. Could there be a link...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Tue, 27 Oct 2009 09:47:40 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/germany.html"><![CDATA[Germany]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/biogen+idec+inc..html"><![CDATA[Biogen Idec Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/microsoft+corp..html"><![CDATA[Microsoft Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[Therapy]]></category>
		<category domain="http://resources.bnet.com/topic/biogen-idec.html"><![CDATA[Biogen-Idec]]></category>
		<category domain="http://resources.bnet.com/topic/tysabri.html"><![CDATA[Tysabri]]></category>
		<category domain="http://resources.bnet.com/topic/pml.html"><![CDATA[PML]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BIIB</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MSFT</category>
		<category domain="tickers">BIIB,MSFT</category>
	</item>
	<item>
		<title><![CDATA[Why Biogen Idec Is Likely to Flinch Before Facet Biotech in Their Game of Chicken]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005023/why-biogen-idec-is-likely-to-flinch-before-facet-biotech-in-their-game-of-chicken/]]></link>
		<description><![CDATA[Biogen Idec's attempted hostile takeover of Facet Biotech, its partner on the potential blockbuster multiple sclerosis drug daclizumab, isn't going according to plan. And the snippy back-and-forths between the two companies are starting to ring with desperation. by Trista Morrison]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Mon, 26 Oct 2009 22:18:40 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biogen+idec+inc..html"><![CDATA[Biogen Idec Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/games.html"><![CDATA[Games]]></category>
		<category domain="http://resources.bnet.com/topic/personal+technology.html"><![CDATA[Personal Technology]]></category>
		<category domain="http://resources.bnet.com/topic/trista+morrison.html"><![CDATA[Trista Morrison]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BIIB</category>
		<category domain="tickers">BIIB</category>
	</item>
	<item>
		<title><![CDATA[Whatever Tysabri Outcome, Biogen Idec Should Survive]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10005002/whatever-tysabri-outcome-biogen-idec-should-survive/]]></link>
		<description><![CDATA[Biogen Idec's key multiple sclerosis drug is in the news again, as the European Medicines Agency EMEA has started a safety review of Tysabri, citing more confirmed cases of a rare -- but potentially fatal -- viral infection of the brain, called progressive multifocal leukoencephalopathy PML, previously linked to the...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Mon, 26 Oct 2009 11:21:30 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/biogen+idec+inc..html"><![CDATA[Biogen Idec Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[Therapy]]></category>
		<category domain="http://resources.bnet.com/topic/tysabri.html"><![CDATA[Tysabri]]></category>
		<category domain="http://resources.bnet.com/topic/progressive+multifocal+leukoencephalopathy.html"><![CDATA[Progressive Multifocal Leukoencephalopathy]]></category>
		<category domain="http://resources.bnet.com/topic/avonex.html"><![CDATA[Avonex]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BIIB</category>
		<category domain="tickers">BIIB</category>
	</item>
	<item>
		<title><![CDATA[DotW: Same As The Old Boss]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/dotw-boss/17307/]]></link>
		<description><![CDATA[Whiners, do-gooders and underdogs, go back to bed. Make yourselves some herbal tea. Go write in your journal or do a little scrapbooking. Maybe you'll feel better.This was not your week, in which we saw nothing less than the restoration of the natural order of the universe. Here's to the...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Fri, 23 Oct 2009 12:55:41 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/advanced+micro+devices+inc..html"><![CDATA[Advanced Micro Devices Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/discovery.html"><![CDATA[discovery]]></category>
		<category domain="http://resources.bnet.com/topic/biogen+idec+inc..html"><![CDATA[Biogen Idec Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/novartis+ag.html"><![CDATA[Novartis AG]]></category>
		<category domain="http://resources.bnet.com/topic/alcon.html"><![CDATA[Alcon]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">AMD</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ACL</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BIIB</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NVS</category>
		<category domain="tickers">AMD,ACL,BIIB,NVS</category>
	</item>
	<item>
		<title><![CDATA[Biogen Idec Inc. Q3 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-354323.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator  Operator Instructions Your first question comes from Eric Schmidt with Cowen And Company.      Eric Schmidt - Cowen And Company        My question is on the opportunistic infections that Al mentioned regarding Ocrelizumab.  I am...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 20 Oct 2009 11:14:07 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/infection.html"><![CDATA[Infection]]></category>
		<category domain="http://resources.bnet.com/topic/label.html"><![CDATA[Label]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/biogen+idec+inc..html"><![CDATA[Biogen Idec Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/security.html"><![CDATA[Security]]></category>
		<category domain="http://resources.bnet.com/topic/strategy.html"><![CDATA[Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/management.html"><![CDATA[Management]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BIIB</category>
		<category domain="tickers">BIIB</category>
	</item>
</channel>
</rss>
